In Brief: Bristol’s Nivolumab Shows Survival, Boehringer Gains A Breakthrough & Sentinel Takes On Flu Vaccines, Plus CHMP Opinions
Executive Summary
Bristol’s early stop of a nivolumab trial in melanoma offers the first late-stage, randomized survival data for the PD-1 class; Boehringer’s Pradaxa antidote is on the breakthrough track; CHMP clears Bristol’s daclatasvir ahead of FDA; and FDA concludes flu vaccines aren’t linked to seizures.